BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27310329)

  • 1. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
    Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
    Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
    BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
    Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
    Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
    Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
    Zou C; Yang Q; Yang S; Zhang X; Yang X; Huang Z; Pei Q; Huang J; Yang G
    Pulm Pharmacol Ther; 2020 Apr; 61():101902. PubMed ID: 32045673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
    Respir Med; 2021; 180():106311. PubMed ID: 33711782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
    Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
    Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
    Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
    Jiang J; Li L; Yin H; Woessner R; Emotte C; Li R; Khindri S; Pei H
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):203-8. PubMed ID: 24705947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
    Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
    Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers.
    Affrime MB; Cuss F; Padhi D; Wirth M; Pai S; Clement RP; Lim J; Kantesaria B; Alton K; Cayen MN
    J Clin Pharmacol; 2000 Nov; 40(11):1227-36. PubMed ID: 11075308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.